Official Sections CTRMS ISVCA IPITA IPTA ISODP IRTA IXA SPLIT TID


Statement on COVID-19 Vaccination in Solid Organ Transplant Recipients

Recently, multiple studies have been published examining the response to SARS-CoV-2 mRNA-based vaccines in solid organ transplant (SOT) recipients.(1-7) Overall, these have demonstrated reduced antibody
The low antibody response rate is concerning but not unexpected as SOT recipients have lower rates of immune responses to other vaccines as well.(8) Further data are needed to evaluate B- and T- cellular responses in SOT recipients after SARS-CoV-2 vaccination and to assess vaccine effectiveness particularly for protection against severe COVID-19 as a clinical end-point. Previous experience with influenza vaccination in transplant patients has demonstrated reduced influenza-related lower respiratory tract disease and hospitalization despite low antibody response.(9, 10). While breakthrough cases of COVID-19 after partial or full vaccination in SOT recipients may occur, it is important to recognize that we may be preventing more cases or reducing severity through vaccination.(11, 12) Thus, we strongly caution against concluding that low antibody response rate to SARS-CoV-2 vaccination will lead to reduced clinical effectiveness until more information is available. These results should not prompt or encourage vaccine hesitancy in SOT recipients.
Immunosuppressed patients are known to have prolonged viral shedding of actively replicating virus which may promote the development of viral variants.(13) Additionally, there are data to suggest worse outcomes in SOT recipients with COVID-19 compared to the general population.(14) The effect of immunization on duration of viral shedding and clinical outcomes remains unknown for this population.

Until more complete data are available, we urge:

  • Pre-transplant vaccination of all SOT candidates as a priority whenever feasible.
  • Continued SARS-CoV-2 vaccination in SOT recipients and priority for vaccination of their household members and caregivers to reduce exposure risk for these vulnerable patients.
  • Continuation of a stable immunosuppression regimen at the time of vaccination to avoid the risk of organ rejection until more comprehensive data are available.
  • Continued adherence of all transplant recipients to protective measures including masking and social distancing regardless of vaccination status.

References (click to view)
  1. Boyarsky BJ, Werbel WA, Avery RA, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA 2021.
  2. Benotmane I, Gautier-Vargas G, Cognard N, et al.: Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int 2021.
  3. Sattler A SE, Weber U, Potekhin A, Bachmann F, Budde K, Storz E, Proß V, Bergmann Y, Thole L, Tizian C, Hölsken O, Diefenbach A, Schrezenmeier H, Jahrsdörfer B, Zemojtel T, Jechow K, Conrad C, Lukassen S, Stauch D, Lachmann N, Choi M, Halleck F, Kotsch K. MedRxv. doi: https://doi.org/10.1101/2021.04.06.21254963. Accessed 4/19/2021: Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients.
  4. Yi SG, Knight RJ, Graviss EA, et al.: Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration. Transplantation 2021.
  5. Peled Y RE, Lavee J, Sternik L, Segev A, Wieder-Finesod A, Mandelboim M, Indenbaum V, Levy I, Raanani E, Lustig Y, Rahav G: BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response. J Heart Lung Transplant 2021.
  6. Narasimhan M ML, Clark AE, Usmani A, Cao J, Raj E, Torres F, Sarode R, Kaza V, Lacelle C, Muthukumar A: Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. medRxiv 2021.
  7. Shostak Y SN, Heching M, Rosengarten D, Shtraichman O, Shitenberg D, Amor SM, Yahav D, Zvi HB, Pertzov B, Kramer MR: Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. The Lancet Resp Med 2021.
  8. Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T: Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One 2013;8:e56974.
  9. Kumar D, Ferreira VH, Blumberg E, et al.: A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. Clin Infect Dis 2018;67:1322-9.
  10. Pinana JL, Perez A, Montoro J, et al.: Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. Clin Infect Dis 2019;68:1894-903.
  11. Basic-Jukic N, Jelicic I: SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients. Transpl Infect Dis 2021:e13628.
  12. Wadei HM GT, Leoni JC, Shah SZ, Aslam N, Speicher LL., COVID-19 infection in Solid Organ Transplant Recipients after SARS-CoV-2 vaccination. Am J Transplant 2021.
  13. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al.: Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med 2020;383:2586-8.
  14. Nair V, Jandovitz N, Hirsch JS, et al.: An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients. Am J Transplant 2020.

Join us for the TTS Masterclass Series

Delivered by the world’s best known and regional experts, each Masterclass includes presentations by an international and a regional expert to bring perspective to the topic, highlight differences and opportunities, and bolster active discussions.

Highlighted Tweets


Webinars (Upcoming and Recordings)

New June 9, 2021 MESOT Webinar

The Middle East Society For Organ Transplantation (MESOT) invites you to the 2nd webinar on How to Increase Deceased Organ Donation during the Covid-19 Era.

Save the Date!

The International Society for Organ Donation and Procurement (ISODP) will be organizing three webinars in November 2021. Details will be published on their website (www.isodp.org) in the coming weeks.

IXA-CTRMS are pleased to announce the extension of the abstract submission deadline until June 1, 2021.

We thank all authors from across the world who have already completed their submission. Please note that there will be no further extension to the deadline.

For guidelines and to submit your abstract click here


New Course from the DICG

The course is open to all participants who want to learn about ethics in transplantation, the DOI and the DICG

Highlighted News

Human Antibodies Target Many Parts of Coronavirus Spike Protein

May 20 - For many people who’ve had COVID-19, the infections were thankfully mild and relatively brief. But these individuals’ immune systems still hold onto enduring clues about how best to neutralize SARS-CoV-2, the coronavirus that causes COVID-19. Discovering these clues could point the way for researchers to design highly targeted treatments that could help to save the lives of folks with more severe infections.


Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada